Things
The Call is promoted by the University of Milan and has the objective of: • adapting and validating technologies that are currently available and in line with current legislation, for the research and development of RNA drugs; • create new tailor-made technologies that allow us to accelerate the research and development of RNA drugs and that facilitate the transition from preclinical research to the clinic with particular emphasis on the use of imaging and biomarker technologies; • develop innovative regulatory strategies.
Who is it aimed at?
The following can request the benefits referred to in this Notice: – Micro, Small and Medium Enterprises (MSMEs) – Large Enterprises (GI); – Public research bodies and institutions, including universities, and the bodies referred to in Legislative Decree no. 218/2016 (https://www.mur.gov.it/it/aree-tematiche/ricerca/il-sistema-della-ricerca/entidi-ricerca-pubblici); – Scientific Hospitalization and Care Institutes – IRCCS, which are public or private in nature; – Entities referred to in the Third Sector Code – Legislative Decree no. 117 of 3 July 2017 and subsequent amendments.
What does it predict
The project proposals must include Fundamental Research, Industrial Research and Experimental Development activities
